{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:36:12Z","timestamp":1740137772984,"version":"3.37.3"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>\n            Introduction\u2003Coronavirus disease is a clinical challenge for patients with autoimmune conditions. Patients affected by immune thrombotic thrombocytopenic purpura (iTTP) are particularly vulnerable to SARS-CoV-2 infection. Protecting these patients with vaccination is therefore mandatory, although concerns may exist on a possible increased thrombotic risk or risk of disease relapse after vaccine exposure. So far, there is no information on serological response and hemostatic activation in iTTP patients after SARS-CoV-2 vaccination.<\/jats:p><jats:p>\n            Materials and Methods\u2003In this study, in April 2021, we enrolled iTTP patients in clinical remission and on regular outpatient follow-up to receive the first and second dose BNT162b2 vaccine as a part of a prospective trial aimed at monitoring for 6 months after vaccination the occurrence of subclinical laboratory signs of clotting activation, as well as overt thrombotic complications or disease relapse. The seroconversion response was monitored in parallel. The results were compared with those of control non-iTTP subjects.<\/jats:p><jats:p>\n            Results\u2003A moderate decrease of ADAMTS-13 activity was recorded at 3 and 6 months in five patients with normal values at baseline, while an ADAMTS-13 relapse occurred at 6 months in one patient. Abnormalities in the endothelium activation biomarkers postvaccination were observed in iTTP patients compared with controls. The immunological response to vaccine was overall positive. No clinical iTTP relapses or thrombotic events manifested in the 6 month-follow-up after vaccination.<\/jats:p><jats:p>\n            Conclusion\u2003The results of this study are in favor of efficacy and safety of mRNA vaccines in patients with iTTP, and highlight the importance of long-term monitoring of iTTP patients.<\/jats:p>","DOI":"10.1055\/s-0043-1768921","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T23:37:01Z","timestamp":1683934621000},"page":"945-954","source":"Crossref","is-referenced-by-count":0,"title":["Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study"],"prefix":"10.1055","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-2000","authenticated-orcid":false,"given":"Francesca","family":"Schieppati","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gamba","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano Bicocca, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Giaccherini","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen J.","family":"Tartari","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bolognini","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Verzeroli","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Ticozzi","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Barcella","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-3457","authenticated-orcid":false,"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"B S Joly","year":"2017","journal-title":"Blood"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17474086.2020.1750361","article-title":"Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents","volume":"13","author":"A G\u00f3mez-De Le\u00f3n","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"J A Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics","volume":"15","author":"M Saha","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00277-020-04097-0","article-title":"Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19","volume":"99","author":"N Albiol","year":"2020","journal-title":"Ann Hematol"},{"issue":"12","key":"ref6","first-page":"002143","article-title":"Critical care COVID-19 patient with a picture of thrombotic thrombocytopenic purpura","volume":"7","author":"R Y Al-Ansari","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"107397","DOI":"10.1016\/j.intimp.2021.107397","article-title":"COVID-19 associated thrombotic thrombocytopenic purpura (TTP); A case series and mini-review","volume":"93","author":"H A Tehrani","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/jth.15231","article-title":"Thrombotic thrombocytopenic purpura as the initial presentation of COVID-19","volume":"19","author":"M C Beaulieu","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","article-title":"Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative","volume":"4","author":"K M Andersen","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1055\/s-0040-1714350","article-title":"Different hypercoagulable profiles in patients with COVID-19 admitted to the internal medicine ward and the intensive care unit","volume":"120","author":"A Boscolo","year":"2020","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1055\/s-0040-1718735","article-title":"Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19","volume":"120","author":"S Gencer","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"441.e3","DOI":"10.1016\/j.ajem.2021.05.001","article-title":"Thrombotic thrombocytopenic purpura after Ad26.COV2-S vaccination","volume":"49","author":"A Yocum","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2021.279535","article-title":"Immune-mediated thrombotic thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine","volume":"107","author":"G Giuffrida","year":"2022","journal-title":"Haematologica"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/jth.15418","article-title":"First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination","volume":"19","author":"S de Bruijn","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jha2.342","article-title":"Acquired thrombotic thrombocytopenic purpura following Pfizer COVID-19 vaccination","volume":"3","author":"M Alislambouli","year":"2021","journal-title":"eJHaem"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3324\/haematol.2022.280702","article-title":"Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study","volume":"107","author":"G Giuffrida","year":"2022","journal-title":"Haematologica"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0042-1744301","article-title":"Acquired thrombotic thrombocytopenic purpura: a rare coincidence after COVID-19 mRNA vaccine?","volume":"49","author":"A CY Tso","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jth.15632","article-title":"Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine: comment from Doyle et al","volume":"20","author":"A J Doyle","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref19","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood.2021015149","article-title":"Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination","volume":"139","author":"A Picod","year":"2022","journal-title":"Blood"},{"issue":"16","key":"ref20","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2022015545","article-title":"SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura","volume":"139","author":"H Shah","year":"2022","journal-title":"Blood"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study","volume":"174","author":"P Deepak","year":"2021","journal-title":"Ann Intern Med"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"A Cuker","year":"2021","journal-title":"Blood"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.25845","article-title":"Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: a multi-institutional study","volume":"95","author":"F Schieppati","year":"2020","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"870599","DOI":"10.3389\/fphar.2022.870599","article-title":"Profiling COVID-19 vaccine adverse events by statistical and ontological analysis of VAERS case reports","volume":"13","author":"W Guo","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"e238026","DOI":"10.1136\/bcr-2020-238026","article-title":"COVID-19 presenting as thrombotic thrombocytopenic purpura (TTP)","volume":"13","author":"E Altowyan","year":"2020","journal-title":"BMJ Case Rep"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.thromres.2020.07.005","article-title":"Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: report of a case","volume":"195","author":"F Hindilerden","year":"2020","journal-title":"Thromb Res"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11239-020-02362-7","article-title":"A case of thrombotic thrombocytopenic purpura associated with COVID-19","volume":"52","author":"D Nicolotti","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.htct.2021.02.003","article-title":"Thrombotic thrombocytopenic purpura associated with COVID-19 in a pediatric patient: case report","volume":"43","author":"C MT Hidalgo Filho","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/jth.15420","article-title":"Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine","volume":"19","author":"H Maayan","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-021-03190-y","article-title":"Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine","volume":"114","author":"S HB Waqar","year":"2021","journal-title":"Int J Hematol"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00277-021-04584-y","article-title":"Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine","volume":"101","author":"J Ruhe","year":"2022","journal-title":"Ann Hematol"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.42058","article-title":"Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases","volume":"74","author":"S Bitoun","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41408-021-00546-9","article-title":"Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab","volume":"11","author":"C Cattaneo","year":"2021","journal-title":"Blood Cancer J"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1038\/s41598-022-11857-7","article-title":"Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures","volume":"12","author":"B Fattizzo","year":"2022","journal-title":"Sci Rep"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.18578","article-title":"Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia","volume":"200","author":"A Mori","year":"2023","journal-title":"Br J Haematol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","article-title":"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups","volume":"125","author":"C Ferri","year":"2021","journal-title":"J Autoimmun"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"V Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1538-7836.2009.03433.x","article-title":"The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission","volume":"7","author":"E Groot","year":"2009","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1768921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T23:24:21Z","timestamp":1695770661000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1768921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1768921","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"type":"print","value":"0340-6245"},{"type":"electronic","value":"2567-689X"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}